All News
RheumNow Podcast – Scleroderma and the Lung (3.1.19)
Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com
Read Article
RheumNow Podcast - Death and Surgery (2-22-19)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com:
Read Article
Impressive Survival of Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis
The drug retention rate of interleukin-1 inhibitors (IL-1) used to treat systemic juvenile idiopathic arthritis (JIA) appears to be quite high according to a new study.
Read Article
Psoriatic Arthritis Does Not Add to Pregnancy Problems
When psoriatic arthritis (PsA) patients become pregnant, they do not have more infertility or adverse pregnancy outcomes compared to healthy controls.
Read Article
Patients Don't Always Tell the Truth
Sometimes patients withhold information from their doctors, and a new study suggests that as much as 60 - 80% of patients consciously omit information to their doctors, despite knowing this may bear on their health and well-being.
Read Article
RheumNow Podcast – Can RA Be Prevented (12.7.18)
Dr. Jack Cush reviews the news and new journal articles from the past week on RheumNow.com:
Read Article
First FDA Approved Drug for HLH
The first drug specifically for primary hemophagocytic lymphohistiocytosis (HLH) was approved today, the FDA announced.
Read Article
The RheumNow Podcast – Heartbreak of Methotrexate (11.16.18)
Dr. Jack Cush reviews the news from the past week at RheumNow.com.
Read Article
Pilot Data on Rituximab in Henoch-Schonlein Purpura
Management of Henoch-Schonlein purpura (HSP) can be challenging as supportive care and avoidance of corticosteroids are often insufficient options. A new series of case reports and literature review of steroid refractory HSP suggests that rituximab may be effective in reducing hospital admissions, overall steroid use, and is capable of inducing remission.
Read Article
Apremilast Succeeds in Scalp Psoriasis
Celgene has announced results from the phase 3 STYLE study, showing apremilast yielding significant improvement in moderate-to-severe scalp psoriasis. STYLE is a phase 3, multicenter, randomized, placebo-controlled, double-blind study evaluating the efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis of the scalp. The study enrolled 303 people who were randomized 2:1 to receive apremilast 30 mg twice daily or placebo for the first 16 weeks.
Read Article
IL-6 for Adult Still's: A New Option?
Some clinical benefits were seen among patients with adult-onset Still's disease treated with tocilizumab (Actemra) in a small clinical trial, but the study's primary endpoint was not met, Japanese researchers reported.
Read Article
Teenage Obesity Increases Lupus Risk
Analysis of the Black Women's Health Study shows that obesity as a teenager may be associated with increased risk of systemic lupus erythematous (SLE) in adulthood.
Read Article
SLE-Scleroderma Overlap Outcomes
Overlap of autoimmune disorders represents a significant diagnostic and management challenge to the rheumatologist. A novel cohort analysis of overlap between systemic sclerosis (SSc) and systemic lupus erythematous (SLE) suggests such patients tend to be younger, more frequently have PAH, but less cutaneous manifestations of SSc.
Read Article
RheumNow Week in Review – Vitamin D Falls Again (10.4.18)
Dr. Jack Cush reviews the news from the past week on RheumNow.com.
Read Article
Predictive Risk Factors for Uveitis in JIA
Researchers from Germany have studied a large cohort of juvenile idiopathic arthritis (JIA) patients and shown that JIA disease activity scores and laboratory biomarkers could be used to better define the group of JIA patients at high risk of uveitis onset.
Read Article
Long-Term Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis
Only inhibitors of IL-1 (canakinumab) and IL-6 (tocilizumab) are FDA approved for use in children with systemic onset juvenile idiopathic arthritis (sJIA). Now, long-term data from the extension studies from two phase III studies shows that canakinumab yields long-term improvements with reduced glucocorticoid dosing with no new safety findings with long-term use.
Read Article
Treatment Preferences in Still’s Disease
In July 2018, RheumNow launched a “Live Vote” survey of US and non-US rheumatologists that asked how they diagnose and treat systemic juvenile idiopathic arthritis (sJIA), also known as “Still’s disease”. It appears that many prefer to start therapy with an IL-1 inhibitor, after a course of steroids and MTX/DMARD. Yet, these findings suggest there are significant unmet needs in the diagnosis and management of sJIA patients.
Read Article
Maternal RA Increases Offspring Risk of Autoimmune Disorders
A Danish population study suggests that fetal exposure to maternal rheumatoid arthritis results in an increased offspring risk of thyroid disease, epilepsy and RA, compared to children born to mothers without RA.
Read Article
The RheumNow Week in Review – Lupus in the News (7.27.18)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.
Read Article
Consensus Guidelines for Methotrexate in Juvenile Idiopathic Arthritis
A consensus panel was convened to develop consensus-based clinical and therapeutic recommendations for the use of methotrexate (MTX) in the management of Juvenile Idiopathic Arthritis (JIA) patients.
Read Article